Skip to content


  • Poster presentation
  • Open Access

Influence of TIMP-1/MMP-9 ratio on the severity and mortality in sepsis

  • 1,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 1 and
  • 7
Critical Care201115 (Suppl 1) :P277

  • Published:


  • Severe Sepsis
  • Septic Patient
  • Plasminogen Activator Inhibitor
  • Inhibit Platelet Aggregation
  • Sofa Score


The role of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in sepsis remains unclear. MMPs play a role facilitating the recruitment of leucocytes from the bloodstream (by proteolysis of the basement membrane) and modulating inflammatory response [1]. Besides, there has been reported a positive association between circulating levels of TIMP-1 and plasminogen activator inhibitor (PAI)-1 in healthy adults [2] and myocardial infarction [3]. In addition there are in vitro studies showing that MMP-9 inhibits platelet aggregation [4, 5]. Thus a high TIMP-1/MMP-9 ratio could contribute to a prothrombotic state, and the development of organ dysfunction and finally death in septic patients. The objectives of this study were to investigate the time course of MMP-9, MMP-10 and TIMP-1 levels, and the association with sepsis severity and PAI-1 levels.


This was a multicenter, observational and prospective study carried out in six Spanish ICUs. We included 192 (125 surviving and 67 nonsurviving) patients with severe sepsis. We obtained blood samples at three moments (time of diagnosis, 72 hours and 7 days) for the determination of MMP-9, TIMP-1, TNFα, IL-10 and PAI-1 levels. We assessed survival at 30 days as the endpoint.


Nonsurvivor patients showed at the three moments lower MMP-9 levels, higher TIMP-1 levels and higher TIMP-1/MMP-9 ratios than survivors. There were at the three moments an association of the TIMP-1/MMP-9 ratio with lactic acid levels, SOFA score, PAI-1 levels, TNFα and IL-10. Logistic regression analysis showed that TIMP-1 levels, lactic acid levels and SOFA score were associated with death at 30 days.


To our knowledge, this study includes the largest series reporting data on MMP levels in sepsis. The novel findings of our study are that nonsurviving septic patients showed a persistent higher TIMP-1/MMP-9 ratio during the first week than survivors. From a therapeutic perspective, the development of modulators of MMP/TIMP activity could be used as a new class of drugs for the treatment of severe sepsis.

Authors’ Affiliations

Hospital Universitario de Canarias, La Laguna, Spain
Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain
Hospital Clínico Universitario de Valencia, Spain
Hospital San Jorge, Huesca, Spain
Hospital Insular, Las Palmas de Gran Canaria, Spain
CIMA-Universidad de Navarra, Pamplona, Spain


  1. Elkington PT, et al.: Clin Exp Immunol. 2005, 142: 12-20. 10.1111/j.1365-2249.2005.02840.xPubMed CentralView ArticlePubMedGoogle Scholar
  2. Aznaouridis K, et al.: Atherosclerosis. 2007, 195: 212-215. 10.1016/j.atherosclerosis.2006.12.015View ArticlePubMedGoogle Scholar
  3. Cavusoglu E, et al.: Am Heart J. 2006, 151: 1101.e1-1101.e8. 10.1016/j.ahj.2006.02.029View ArticleGoogle Scholar
  4. Sheu JR, et al.: Br J Pharmacol. 2004, 143: 193-201. 10.1038/sj.bjp.0705917PubMed CentralView ArticlePubMedGoogle Scholar
  5. Lee YM, et al.: Eur J Pharmacol. 2006, 537: 52-58. 10.1016/j.ejphar.2006.03.031View ArticlePubMedGoogle Scholar


© Lorente et al. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.